Monoclonal Antibodies in Newly Diagnosed Myeloma - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Using Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma with Peter Voorhees, MD, Levine Cancer Institute

Using Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma with Peter Voorhees, MD, Levine Cancer Institute image

Using Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma with Peter Voorhees, MD, Levine Cancer Institute

Podcast
event May 18, 2021 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Peter Voorhees, MD
Levine Cancer Institute - Atrium Health
Interview Date: May 18, 2021

Quad therapies (four combined myeloma treatments) are becoming more popular, even for newly diagnosed myeloma patients. In this show, Dr. Peter Voorhees of the Levine Cancer Institute shares details about how the addition of a monoclonal antibody like daratumumab, isatuximab or elotuzumab may be used in combination with other standard myeloma treatments for newly diagnosed patients. This is a major shift for newly diagnosed patients to use these monoclonal antibodies in earlier lines of therapy instead of reserving these new treatment drug classes for later use. 

Thanks to our episode sponsor

Schedule & Agenda

Event panelist Dr. Peter Voorhees & Jenny Ahlstrom
11:00 AM
Discussion
Dr. Peter Voorhees & Jenny Ahlstrom

Speakers & Moderators

The panelist Peter Voorhees, MD
Peter Voorhees, MD

Peter Voorhees, MD, is Director of Outreach and Clinical Operations for Hematologic Malignancies and a Member of the Plasma Cells Disorder Program at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees is an internationally recognized thought leader in multiple myeloma whose research focuses on the clinical development of novel therapeutic strategies for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. He is board certified in Hematology and a member of the American Society of Hematology, American Society of Clinical Oncology and International Myeloma Working Group. He is also a member of the Multiple Myeloma Committee of the Alliance Cooperative Group. He has published numerous original articles, reviews and book chapters in multiple myeloma. He received his medical degree from the University of Michigan, continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and completed a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Prior to joining the Levine Cancer Institute, he was an Associate Professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill where he led their Multiple Myeloma Program.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.